Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21WAF1/CIP1 proteins in human acute lymphoblastic leukemia cells

Blood

Volumn 99, Issue 9, 2002, Pages 3390-3397

  Ogawa, Ryosuke ^a   Streift, Michael B ^a   Bugayenko, Artem ^a   Kato, Gregory J ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Ross Research Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; CYCLIC AMP; DEXAMETHASONE; FORSKOLIN; GLUCOCORTICOID; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PROTEIN P21; PROTEIN P53; ROLIPRAM; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION;

EID: 0036566204     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3390     Document Type: Article

References (64)

1. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
2. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia
3. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)
4. Glucocorticoid receptors and steroid sensitivity in normal and neoplastic human lymphoid tissues: A review
5. Glucocorticoid receptors predict response to combination chemotherapy in patients with acute lymphoblastic leukemia
6. Glucocorticoid receptors and sensitivity in leukemias
7. Clinical implications of glucocorticoid receptors in human leukemia
8. Glucocorticoid receptors in childhood acute lymphocytic leukemia
9. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: A Pediatric Oncology Group Study
10. High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia
11. Cellular receptor levels and glucocorticoid responsiveness of lymphoma cells
12. Diploid and haploid states of the glucocorticoid receptor gene of mouse lymphoid cell lines
13. Transcriptional control of steroid-regulated apoptosis in murine thymoma cells
14. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells
15. Induction of cytolysis of cultured lymphoma cells by adenosine 3′:5′-cyclic monophosphate and the isolation of resistant variants
16. TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes
17. Distribution of cAMP in secondary follicles and its expression in B cell apoptosis and CD40-mediated survival
18. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes
19. Adenosine receptor-mediated accumulation of cyclic AMP-induced T-lymphocyte death through internucleosomal DNA cleavage
20. Cyclic adenosine-3′,5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma
21. Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production
22. Mechanism of lymphoma cell death induced by cyclic AMP
23. Functional glucocortiCoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line
24. Dopaminergic and ligand-independent activation of steroid hormone receptors
25. -, and glucocorticoid-induced gene expression in lymphocytes
26. Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc
27. Cyclic AMP-dependent protein kinase promotes glucocorticoid receptor function
28. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticold and protein kinase A pathways: Correlation with c-Myc suppression
29. Modulation of glucocorticoid receptor function by protein kinase A
30. Tailoring cAMP-signaling responses through isoform multiplicity
31. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
32. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
33. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation
34. Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes
35. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant
36. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization
37. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes
38. Structure and function of nuclear hormone receptors
39. Cyclic AMP phosphodiesterases in human lymphocytes
40. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes
41. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells
42. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia
43. In vitro and in vivo anti-leukemic efficacy of cyclic AMP modulating agents against human leukemic B-cell precursors
44. Interactions between human immunodeficiency virus infection and hormonal pathways: Enhancement of calcium-induced but reduction of glucocorticoid-induced cell death
45. Characterization of a glucocorticoid-sensitive human lymphoid cell line
46. Identification of the activation-labile gene: A single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes
47. Theophylline, a new inducer of apoptosis in B-CLL: Role of cyclic nucleotides
48. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5
49. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition
50. Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production
51. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells
52. Evidence that glucocorticoid- and cyclic AMP-induced apoptotic pathways in lymphocytes share distal events
53. CyclicAMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes
54. G-proteins: IMPlications for pathophysiology and disease
55. Glucocorticoid receptors in lymphoma cells in culture: Relationship to glucocorticoid killing activity
56. p53 recruitment of CREB binding protein mediated through phosphorylated CREB: A novel pathway of tumor suppressor regulation
57. Thymocyte apoptosis induced by p53-dependent and independent pathways
58. The dose dependent effect of cyclic AMP on ribonucleotide reductase in mitogen stimulated mononuclear cells
59. Cyclic AMP delays G2 progression and prevents efficient accumulation of cyclin B1 proteins in mouse macrophage cells
60. Prevention of tumor necrosis factor (TNF)-mediated induction of p21WAF1/CIP1 sensitizes MCF-7 carcinoma cells to TNF-induced apoptosis
61. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies
62. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
63. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
64. SB 207499 (Arifio)(Ariflo), a potent and selective second-generation genpration phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions